Ertugliflozin: Phase III data

The double-blind, international Phase III VERTIS Mono trial in 461 Type II diabetics inadequately controlled on diet and exercise showed that once-daily 5 and 15 mg ertugliflozin each met the primary endpoint

Read the full 320 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE